TENX Tenax Therapeutics, Inc.
Healthcare$11.98-1.24%ClosedMarket Cap: $206.0M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
4.72
P/S
0.00
EV/EBITDA
-1.49
DCF Value
$2.35
FCF Yield
-18.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-56.3%
ROA
-47.0%
ROIC
-53.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-16.6M | $-15.7M | $— | — |
| Q4 null | $0.00 | NaN% | $-16.4M | $-15.5M | $— | — |
| FY null | $0.00 | NaN% | $-56.4M | $-52.6M | $— | — |
| Q3 null | $0.00 | NaN% | $-16.8M | $-15.8M | $— | — |
| Q2 null | $0.00 | NaN% | $-11.8M | $-10.8M | $— | — |
| Q1 null | $0.00 | NaN% | $-11.3M | $-10.4M | $— | — |
| Q4 null | $0.00 | NaN% | $-7.3M | $-6.3M | $— | — |
| FY null | $0.00 | NaN% | $-19.5M | $-17.6M | $— | — |
| Q3 null | $0.00 | NaN% | $4.6M | $-4.0M | $— | — |
| Q2 null | $0.00 | NaN% | $-3.7M | $-3.6M | $— | — |
| Q1 null | $0.00 | NaN% | $-3.9M | $-3.8M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-3.3M | $-3.2M | $-10.81 | — |